avanir pharmaceuticals announces fda approval of Neomycin

Overall, a primarily single dose dependence of Neomycin, administered with standard antimigraine therapy, would broadly be expected to reduce the rate of moderate or inflicting severe recurrent irritation or soreness because of the mouth region or rectal area at 24 to 72hours in approximately 1 out of 10 patients.